Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: Regulation and counterregulation

Journal of Immunology

Volumn 183, Issue 12, 2009, Pages 7898-7908

  Currie, Andrew J ^a   Prosser, Amy ^a   McDonnell, Alison ^a   Cleaver, Amanda L ^a   Robinson, Bruce W S ^a   Freeman, Gordon J ^b   Van Der Most, Robbert G ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; KI 67 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN DERIVATIVE; PROTEIN ICOS; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; B7 ANTIGEN; MEMBRANE ANTIGEN; MEMBRANE PROTEIN; PDCD1 PROTEIN, MOUSE; PDCD1LG1 PROTEIN, MOUSE; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL POPULATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; LYMPH NODE; MESOTHELIOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; STROMA; T LYMPHOCYTE ACTIVATION; TUMOR CELL CULTURE; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; DRUG ANTAGONISM; DRUG CONTRAINDICATION; FEMALE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; STROMA CELL; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD80; ANTIGENS, SURFACE; APOPTOSIS REGULATORY PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; LYMPH NODES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PEPTIDES; SIGNAL TRANSDUCTION; STROMAL CELLS; T-LYMPHOCYTES, REGULATORY;

EID: 76249090050     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901060     Document Type: Article

References (44)

1. Blank, C., T. F. Gajewski, and A. Mackensen. 2005. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol. Immunother. 54: 307-314. (Pubitemid 40238924)
2. Keir, M. E., M. J. Butte, G. J. Freeman, and A. H. Sharpe. 2008. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26: 677-704. (Pubitemid 351600389)
3. Greenwald, R. J., G. J. Freeman, and A. H. Sharpe. 2005. The B7 family revisited. Annu. Rev. Immunol. 23: 515-548.
4. Sharpe, A. H., E. J. Wherry, R. Ahmed, and G. J. Freeman. 2007. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8: 239-245.
5. Latchman, Y. E., S. C. Liang, Y. Wu, T. Chernova, R. A. Sobel, M. Klemm, V. K. Kuchroo, G. J. Freeman, and A. H. Sharpe. 2004. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl. Acad. Sci. USA 101: 10691-10696.
6. Barber, D. L., E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687.
7. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10: 29-37.
8. Ha, S. J., S. N. Mueller, E. J. Wherry, D. L. Barber, R. D. Aubert, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2008. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J. Exp. Med. 205: 543-555.
9. Blank, C., and A. Mackensen. 2007. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol. Immunother. 56: 739-745. (Pubitemid 46348742)
10. Curiel, T. J., S. Wei, H. Dong, X. Alvarez, P. Cheng, P. Mottram, R. Krzysiek, K. L. Knutson, B. Daniel, M. C. Zimmermann, et al. 2003. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9: 562-567.
11. Thompson, R. H., H. Dong, C. M. Lohse, B. C. Leibovich, M. L. Blute, J. C. Cheville, and E. D. Kwon. 2007. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin. Cancer Res. 13: 1757-1761.
12. Hirano, F., K. Kaneko, H. Tamura, H. Dong, S. Wang, M. Ichikawa, C. Rietz, D. B. Flies, J. S. Lau, G. Zhu, et al. 2005. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65: 1089-1096.
13. He, Y. F., G. M. Zhang, X. H. Wang, H. Zhang, Y. Yuan, D. Li, and Z. H. Feng. 2004. Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine. J. Immunol. 173: 4919-4928.
14. + Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J. Clin. Invest. 119: 551-564.
15. Manning, L. S., D. Whitaker, A. R. Murch, M. J. Garlepp, M. R. Davis, A. W. Musk, and B. W. Robinson. 1991. Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. Int. J. Cancer 47: 285-290.
16. Van der Most, R. G., A. J. Currie, S. Mahendran, A. Prosser, A. Darabi, B. W. S. Robinson, A. K. Nowak, and R. A. Lake. 2009. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector suppressor T cells in limiting effective chemotherapy. Cancer Immunol. Immunother. 58: 1219-1228.
17. Marzo, A. L., R. A. Lake, B. W. Robinson, and B. Scott. 1999. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res. 59: 1071-1079.
18. Broomfield, S., R. G. Van der Most, A. Prosser, S. Mahendran, M. G. Tovey, J. W. Smyth, B. W. Robinson, and A. J. Currie. 2009. Locally administered Toll-like receptor-7 agonists drive systemic anti-tumor immune responses that are enhanced by anti-CD40 immunotherapy. J. Immunol. 182: 5217-5224.
19. Marzo, A. L., R. A. Lake, D. Lo, L. Sherman, A. McWilliam, D. Nelson, B. W. Robinson, and B. Scott. 1999. Tumor antigens are constitutively presented in the draining lymph nodes. J. Immunol. 162: 5838-5845.
20. Vremec, D., M. Zorbas, R. Scollay, D. J. Saunders, C. F. Ardavin, L. Wu, and K. Shortman. 1992. The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. J. Exp. Med. 176: 47-58.
21. Winkel, K., F. Sotzik, D. Vremec, P. U. Cameron, and K. Shortman. 1994. CD4 and CD8 expression by human and mouse thymic dendritic cells. Immunol. Lett. 40: 93-99. (Pubitemid 24175034)
22. Currie, A. J., R. G. van der Most, S. A. Broomfield, A. C. Prosser, M. G. Tovey, and B. W. Robinson. 2008. Targeting the effector site with IFN-αβ-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J. Immunol. 180: 1535-1544.
23. Blank, C., I. Brown, A. C. Peterson, M. Spiotto, Y. Iwai, T. Honjo, and T. F. Gajewski. 2004. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 64: 1140-1145. (Pubitemid 38176921)
24. Blank, C., J. Kuball, S. Voelkl, H. Wiendl, B. Becker, B. Walter, O. Majdic, T. F. Gajewski, M. Theobald, R. Andreesen, and A. Mackensen. 2006. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int. J. Cancer 119: 317-327.
25. Nowak, A. K., R. A. Lake, A. L. Marzo, B. Scott, W. R. Heath, E. J. Collins, J. A. Frelinger, and B. W. Robinson. 2003. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than crosstolerizing host tumor-specific CD8 T cells. J. Immunol. 170: 4905-4913.
26. + T cells. J. Immunol. 165: 5035-5040.
27. Metcalf, R. A., J. A. Welsh, W. P. Bennett, M. B. Seddon, T. A. Lehman, K. Pelin, K. Linnainmaa, L. Tammilehto, K. Mattson, B. I. Gerwin, et al. 1992. p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res. 52: 2610-2615.
28. Gerdes, J., H. Lemke, H. Baisch, H. H. Wacker, U. Schwab, and H. Stein. 1984. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 133: 1710-1715.
29. + T cell responses to smallpox and yellow fever vaccines. Immunity 28: 710-722.
30. + regulatory T cells. Curr. Opin. Immunol. 16: 203-208.
31. + T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J. Exp. Med. 199: 1479-1489.
32. Ito, T., M. Yang, Y. H. Wang, R. Lande, J. Gregorio, O. A. Perng, X. F. Qin, Y. J. Liu, and M. Gilliet. 2007. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J. Exp. Med. 204: 105-115.
33. + T-cell responses in tumor-bearing hosts. Cancer Res. 65: 6984-6989.
34. Freeman, G. J., A. J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L. J. Fitz, N. Malenkovich, T. Okazaki, M. C. Byrne, et al. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192: 1027-1034.
35. + regulatory T cell of non-responders after hepatitis B surface antigen vaccine immunization. Clin. Immunol. 129: 176-177.
36. + T cells acting as regulatory cells during the induction of anterior chamber-associated immune deviation. Invest. Ophthalmol. Visual Sci. 47: 4444-4452.
37. Terabe, M., S. Matsui, J. M. Park, M. Mamura, N. Noben-Trauth, D. D. Donaldson, W. Chen, S. M. Wahl, S. Ledbetter, B. Pratt, et al. 2003. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocytemediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198: 1741-1752.
38. Fichtner-Feigl, S., M. Terabe, A. Kitani, C. A. Young, I. Fuss, E. K. Geissler, H. J. Schlitt, J. A. Berzofsky, and W. Strober. 2008. Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-α2. Cancer Res. 68: 3467-3475.
39. Webster, K. E., S. Walters, R. E. Kohler, T. Mrkvan, O. Boyman, C. D. Surh, S. T. Grey, and J. Sprent. 2009. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J. Exp. Med. 206: 751-760.
40. + T lymphocytes inhibit T cell activation 'in vitro' and attenuate autoimmune encephalitis 'in vivo.' Int. Immunol. 20: 577-589.
41. + effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10. J. Exp. Med. 197: 181-193.
42. Nurieva, R. I., J. Duong, H. Kishikawa, U. Dianzani, J. M. Rojo, I. Ho, R. A. Flavell, and C. Dong. 2003. Transcriptional regulation of Th2 differentiation by inducible costimulator. Immunity 18: 801-811. (Pubitemid 36776429)
43. + Th cells produce distinct cytokines in different mucosal immune responses. Eur. J. Immunol. 33: 392-401.
44. + T regulatory cells: implications and impact on tumor-mediated immune suppression. J. Immunol. 180: 2967-2980.